| Hazard Information | Back Directory | [Uses]
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research[1]. | [in vivo]
| Animal Model: | PD-L1+/? (H358 and ES2) tumor[1] | | Dosage: | 0.01-100 μM | | Administration: | incubation | | Result: | Observed 40-55% higher uptake in PD-L1+ H358 tumors than in wild-type counterparts.
Failed to discriminate between wild-type and knock-out for ES2 slides.
|
| [References]
[1] Wa?yńska MA, et al. Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors. J Med Chem. 2023 Jul 27;66(14):9577-9591. DOI:10.1021/acs.jmedchem.3c00254 |
|
|